1-deoxynojirimycin has been researched along with miglitol in 227 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 31 (13.66) | 18.7374 |
| 1990's | 46 (20.26) | 18.2507 |
| 2000's | 52 (22.91) | 29.6817 |
| 2010's | 86 (37.89) | 24.3611 |
| 2020's | 12 (5.29) | 2.80 |
| Authors | Studies |
|---|---|
| Asano, N; Fleet, GW; Kameda, Y; Kato, A; Kizu, H; Molyneux, RJ; Nash, RJ; Yamashita, T; Yasuda, K | 1 |
| Adachi, I; Asano, N; Ikeda, K; Imahori, T; Kamiyama, O; Kato, A; Kuriyama, C; Okamoto, T; Sanae, F; Takahata, H | 1 |
| Aerts, JM; Bijl, N; Boot, RG; Copeland, D; Ghauharali, K; Groen, AK; Groener, JE; Liu, H; Meijer, AJ; O'Shea, TJ; Ottenhoff, R; Overkleeft, HS; Song, H; van den Berg, RJ; van der Marel, GA; van Eijk, M; Wennekes, T; Yew, N | 1 |
| Adachi, I; Hayashi, E; Hirono, S; Imahori, T; Kato, A; Koseki, J; Miyauchi, S; Nakagome, I; Nash, RJ; Natori, Y; Shimaoka, H; Takahata, H; Yoshimura, Y | 1 |
| Fukui, K; Hatano, A; Iwaki, R; Kanno, Y; Kato, A; Kondo, Y; Okada, M; Sunaga, Y; Umezawa, H; Yamada, H | 1 |
| Frydas, A; Ladas, SD; Papadopoulos, A; Raptis, SA | 1 |
| Dimitriadis, G; Raptis, S | 1 |
| Kingma, PJ; Menheere, PP; Nieuwenhuijzen Kruseman, AC; Sels, JP | 1 |
| Ahrens, K; Arends, J; Lübke, D; Willms, B | 1 |
| DeBouno, JF; Michaelis, OE; Szepesi, B; Tulp, OL | 1 |
| Creutzfeldt, W; Lamberts, R; Lembcke, B; Wöhler, J | 1 |
| Creutzfeldt, W; Ebert, R; Fölsch, UR; Gatzemeier, W; Lembcke, B; Siegel, E | 1 |
| Holman, RR; Steemson, J; Turner, RC | 1 |
| Toeller, M | 1 |
| Inoue, S; Shishido, T | 1 |
| Alexopoulos, E; Dimitriadis, G; Ganotakis, M; Hatziagellaki, E; Komesidou, V; Kordonouri, O; Raptis, S | 1 |
| Bloom, SR; Requejo, F; Uttenthal, LO | 1 |
| Berzin, M; Diamond, TH; Griffiths, RF; Kalk, WJ; Osler, CE; Smit, AM; Wing, J | 1 |
| Foukaridis, GN; Joubert, PH; Venter, HL | 1 |
| Heagerty, AM; MacIver, DH; McNally, PG; Ollerenshaw, JD; Sheldon, TA | 1 |
| Creutzfeldt, W; Diederich, M; Fölsch, UR; Lembcke, B | 1 |
| Gerok, W; Giffhorn-Katz, S; Gross, V; Heinrich, PC; Katz, NR; Kreisel, W; Ludolph, D | 1 |
| Reuser, AJ; van Dongen, JM; Wisselaar, HA | 1 |
| Madar, Z | 2 |
| Gray, RS; Hillman, RJ; Scott, M | 1 |
| Klauser, RM; Prager, RJ; Schernthaner, G; Schnack, C; Schneider, BG; Winkler, J | 1 |
| Heinz, G; Komjati, M; Korn, A; Waldhäusl, W | 1 |
| Goda, T; Koldovský, O; Lee, SM; Samulitis, BK | 1 |
| Bollen, M; Stalmans, W; Vandebroeck, A | 1 |
| Scott, AR; Tattersall, RB | 1 |
| Alberti, KG; Samad, AH; Taylor, R; Ty Willing, TS | 1 |
| Holt, PR; Kotler, DP; Thea, D; Yang, MY | 1 |
| Federlin, K; Hillebrand, I; Laube, H | 1 |
| Dimitriadis, G; Hatziagelaki, E; Hillebrand, I; Ladas, S; Linos, A; Raptis, S | 1 |
| Cañizo, JF; Hillebrand, I; Navascués, I; Sabán, J; Serrano-Rios, M | 1 |
| Gerich, JE; Kennedy, FP | 2 |
| Gerard, J; Hillebrand, I; Lefèbvre, PJ | 1 |
| Creutzfeldt, W; Fölsch, UR; Lembcke, B; Löser, C; Wöhler, J | 1 |
| Gerich, JE; Heiling, V; Kennedy, FP; Miles, JM | 1 |
| Boehme, K; Graefe, KH; Hillebrand, I; Wehling, K | 1 |
| Cauderay, M; Felber, JP; Hillebrand, I; Jéquier, E; Tappy, L; Temler, E | 1 |
| Bam, WJ; Joubert, PH; Manyane, N | 1 |
| Dimitriadis, G; Halvatsiotis, P; Hatziagelaki, E; Hillebrand, I; Ladas, S; Mitrakou, A; Raptis, A; Raptis, S | 1 |
| Luger, A; Röggla, G; Schernthaner, G; Schnack, C | 1 |
| Anastasopoulou, K; Frangaki, D; Hillebrand, I; Katsilambros, N; Marangos, M; Philippides, P; Protopapas, J; Siskoudis, P; Toskas, A; Xefteri, H | 1 |
| Arends, J; Willms, BH | 1 |
| Bopape, ML; Foukaridis, GN; Joubert, PH | 1 |
| Bachmann, W; Hillebrand, I; Lotz, N; Rinninger, F | 1 |
| Barker, HM; Bowey, EA; Canfield, JE; Taylor, RH | 1 |
| Creutzfeldt, W; Fölsch, UR; Lembcke, B | 1 |
| Bozza, M; Corgiat-Mansin, L; Cravero, F; Giorda, C; Marena, S; Pagano, G; Rossi, CM | 1 |
| Lundquist, I; Salehi, A | 1 |
| Reuser, AJ; Wisselaar, HA | 1 |
| Branolte, JH; Kingma, PJ; Menheere, PP; Nieuwenhuijzen Kruseman, AC; Sels, JP; Wolffenbuttel, BH | 1 |
| Coniff, RF; Hoogwerf, BJ; Johnston, PS; Krol, A; Pi-Sunyer, FX; Santiago, JV | 1 |
| Tattersall, R | 1 |
| DeBouno, JF; Michaelis, OE; Tulp, OL | 1 |
| Johnson, AB; Taylor, R | 1 |
| Duursema, L; Groenewoud, G; Hundt, HK; Middle, MV; Müller, FO; Schall, R | 1 |
| Menheere, PP; Nauta, JJ; Nieuwenhuijzen Kruseman, AC; Sels, JP; Wolffenbuttel, BH | 1 |
| Campillo, JE; Martinez, IM; Nieto, M; Ropero, MF; Tormo, MA | 2 |
| Berlin, C; Feig, PU; Petzinna, D; Ratzmann, KP; Rybka, J; Schernthaner, G; Segal, P | 1 |
| Ahr, HJ; Boberg, M; Brendel, E; Krause, HP; Steinke, W | 1 |
| Coniff, RF; Davidson, JA; Feig, PU; Haffner, SM; Johnston, PS; Krol, A | 1 |
| Coniff, RF; Feig, PU; Johnston, PS; Kelley, DE; Krol, A; Mooradian, AD | 1 |
| Coniff, RF; Johnston, PS; Lebovitz, HE; Munera, CL; Raskin, P; Simonson, DC | 1 |
| Bauer, RJ; Mitrakou, A; Raptis, AE; Raptis, SA; Schulz, H; Tountas, N | 1 |
| Chiasson, JL; Rabasa-Lhoret, R | 1 |
| Lardinois, CK | 1 |
| Mooradian, AD; Thurman, JE | 1 |
| Axen, KV; Li, X; Sclafani, A | 1 |
| Dolphin, PJ; Graham, SE; Russell, JC | 1 |
| Andres, E; Blicklé, JF; Brogard, JM | 1 |
| Arai, M; Fujiwara, H; Fujiwara, T; Hashimoto, K; Kariya, T; Kawasaki, M; Minatoguchi, S; Nishida, Y; Takemura, G; Uno, Y | 1 |
| Riddle, MC | 1 |
| Scott, LJ; Spencer, CM | 1 |
| Stadler, HJ | 1 |
| Fehmann, HC | 4 |
| Kuritzky, L; Quillen, DM; Samraj, G | 1 |
| Carlson, RF | 1 |
| Chiou, WL; Chung, SM; Jeong, HY; Ma, C; Wu, TC | 1 |
| Baker, DE; Campbell, LK; Campbell, RK | 1 |
| Huijberts, MS; Sels, JP; Wolffenbuttel, BH | 1 |
| Hanefeld, M; Naditch, L; Raptis, SA; Rybka, J; Schernthaner, G; Standl, E | 1 |
| Chiasson, JL; Naditch, L | 1 |
| Laws, A | 1 |
| Arai, M; Chen, XH; Fujiwara, H; Hashimoto, K; Hashimoto, Y; Minatoguchi, S; Takemura, G; Uno, Y; Wang, N | 1 |
| Maislos, M; Rybka, J; Schernthaner, G; Segal, P; Van Gaal, L | 1 |
| Lefèbvre, PJ; Scheen, AJ | 1 |
| Neye, H | 1 |
| Drent, ML; Hoenderdos, EB; Jonker, JJ; Tollefsen, AT; van der Veen, EA; van Heusden, FH | 1 |
| Horowitz, M; Lee, A; Morley, JE; Patrick, P; Wishart, J | 1 |
| Artés, M; Benito, P; Faure, E; García-Mayor, R; López, JS; Mesa, J; Pallardo, LF; Puig-Domingo, M; Ravella, R | 1 |
| Deppenmeier, U; Hoffmeister, M; Prust, C | 1 |
| Chawla, S; Takiya, L | 1 |
| Fischer, S; Hanefeld, M | 1 |
| Scheen, AJ | 1 |
| Aller, R; Conde Valentín, R; de Luis Román, DA; del Pozo García, E; Romero Bobillo, E | 1 |
| Haslbeck, M; Jakob, S; Kellerer, M; Linn, T | 1 |
| Arai, M; Chen, X; Fujiwara, H; Fujiwara, T; Lu, C; Minatoguchi, S; Takemura, G; Uno, Y; Wang, N | 1 |
| Akkermans, RP; Lucassen, PL; Rutten, GE; Van de Laar, FA; Van de Lisdonk, EH; Van Weel, C | 1 |
| Arai, M; Chen, XH; Fujiwara, H; Hashimoto, K; Lu, C; Minatoguchi, S; Takemura, G; Uno, Y; Wang, N | 1 |
| Hayashi, I; Kuboyama, N; Yamaguchi, T | 1 |
| Boosi, R; Kandikere, VN; Maurya, S; Mudigonda, K; Nirogi, RV; Shukla, M; Yerramilli, A | 1 |
| Fawcett, JP; Gu, J; Li, X; Wang, J; Wang, Y; Zhao, L | 1 |
| Aoki, K; Ito, S; Iwasaki, T; Kimura, M; Nakamura, A; Nezu, U; Takahashi, M; Terauchi, Y | 1 |
| Goda, T; Komori, A; Kumazawa, T; Kuranuki, S; Makita, Y; Mochizuki, K; Suruga, K | 1 |
| Ishimura, I; Kannno, S; Node, K; Yokoyama, H | 1 |
| Aoki, K; Kato, H; Terauchi, Y | 1 |
| Amioka, K; Furuta, Y; Wada, I | 1 |
| Kasuga, M; Sakaguchi, K | 1 |
| Baliga, VP; Jayaram, S; Kinagi, S; Mishra, AB; Periyandavar, I; Rajadhyaksha, GC; Sharma, A; Singh, KP | 1 |
| Arakawa, M; Ebato, C; Fujitani, Y; Hirose, T; Kawamori, R; Mita, T; Shimizu, T; Watada, H | 1 |
| Bhasin, M; Hsieh, M; Sandbhor, M; Williams, DT; Wu, SH; Zou, W | 1 |
| Aoki, K; Nakajima, S; Nezu, U; Shinoda, K; Terauchi, Y | 1 |
| Inoue, T; Node, K; Yokoyama, H | 1 |
| Hirata, A; Igarashi, M; Iwai, H; Tominaga, M | 1 |
| Cohen, S; Coste, S; Guffon-Fouilhoux, N; Guillaumont, M; Guitton, J; Manchon, M | 1 |
| Fukaya, N; Goda, T; Mochizuki, K; Shimada, M; Tanaka, Y | 2 |
| Fukaya, N; Goda, T; Mochizuki, K; Shimada, M | 1 |
| Fujita, H; Hosoba, M; Katsuura, Y; Morii, T; Narita, T; Sato, T; Yamada, Y | 1 |
| Babu, RK; Deshpande, MC; Trivedi, RK; Venkateswarlu, V | 1 |
| Csuk, R; Prell, E | 1 |
| Fuchigami, M; Fukaya, N; Goda, T; Jiuxin, Z; Kumazawa, T; Mochizuki, K; Tanaka, Y | 1 |
| Hosoba, M; Kakei, M; Nanjo, H; Narita, T; Sato, T; Satoh, K; Uchinami, H; Yamada, Y; Yamamoto, Y | 1 |
| Goda, T; Hanai, E; Kuranuki, S; Mochizuki, K; Suruga, K | 1 |
| Adelman, MH; Monte, SV; Paladino, JA; Schentag, JJ | 1 |
| Aoki, K; Masuda, K; Miyazaki, T; Terauchi, Y; Togashi, Y | 1 |
| Aoki, K; Miyazaki, T; Nagakura, J; Orime, K; Terauchi, Y; Togashi, Y | 1 |
| Daida, H; Fukao, K; Fukushima, Y; Hiki, M; Hirose, K; Kiyanagi, T; Kume, A; Kurata, T; Matsumori, R; Miida, T; Miyazaki, T; Ohmura, H; Ohsaka, H; Shimada, K; Sumiyoshi, K | 1 |
| Aoki, K; Ito, Y; Muraoka, T; Terauchi, Y; Togashi, Y | 1 |
| Kawamori, R; Nemoto, M; Tajima, N | 1 |
| Fuchigami, M; Fukaya, N; Goda, T; Inoue, S; Mochizuki, K; Muramatsu, T; Osonoi, T; Saito, M | 1 |
| Aizawa, S; Fujii, H; Fukui, H; Kato, S; Kojima, K; Makutani, S; Mochi, T; Morimoto, T; Sawai, M; Tsujimoto, T; Yamamoto, K; Yasuhara, Y; Yoshioka, S | 1 |
| Abiko, A; Araki, S; Haneda, M; Itoh, H; Koya, D; Maegawa, H; Nakagawa, A; Nishizawa, M; Uzu, T; Yokomaku, Y; Yokoyama, H | 1 |
| Csuk, R; Kluge, R; Korb, C; Prell, E; Ströhl, D | 1 |
| Chou, CW; Chu, CH; Hsieh, SH; Shih, KC | 1 |
| Deshpande, MC; Gadewar, ST; Mantri, AH; Venkateswarlu, V | 1 |
| Morimoto, A; Nishimura, R; Tajima, N; Taki, K; Tsujino, D; Utsunomiya, K | 1 |
| An, N; Dai, XM; Li, HY; Wu, JM; Zhang, QM | 1 |
| Aoyama, T; Fujiwara, H; Hattori, A; Iwasa, M; Kawamura, I; Kobayashi, H; Minatoguchi, S; Nishigaki, K; Shiraki, T; Sumi, S; Takemura, G; Ushikoshi, H; Yamada, Y; Yamaki, T; Yasuda, S | 1 |
| Dwivedi, A; Jain, R; Lukram, O | 1 |
| Fuchigami, M; Fukaya, N; Goda, T; Mochizuki, K; Tanaka, Y | 1 |
| Avery, S; Jones, K; Kumarasamy, J; Liu, H; Mohan, S; Naim, HY; Nichols, BL; Pinto, BM; Quezada-Calvillo, R; Rose, DR; Sim, L | 1 |
| Hamaguchi, T; Katsuno, T; Konishi, K; Kusunoki, Y; Miuchi, M; Miyagawa, J; Murai, K; Nagai, E; Namba, M; Ochi, F; Tokuda, M | 1 |
| Aoki, K; Kamiyama, H; Masuda, K; Shibuya, M; Terauchi, Y; Yoshimura, K | 1 |
| Emoto, T; Hashimoto, M; Iwasaki, M; Kageyama, H; Kim, SK; Matsuo, Y; Mizoguchi, T; Mizuguchi, T; Motodi, Y; Okamoto, H; Sawada, T; Taira, K; Takarada, A; Terashita, D; Yokoyama, M | 1 |
| Bai, F; Bai, G; Cao, X; Geng, P; Ren, L | 1 |
| Fujita, H; Hosoba, M; Morii, T; Narita, T; Sato, T; Tsukiyama, K; Yamada, Y; Yamashita, R; Yokoyama, H | 1 |
| Kishimoto, M; Noda, M | 2 |
| Fukuda, H; Fuse, J; Ishii, S; Katabami, T; Kato, H; Kobayashi, H; Kobayashi, S; Kondo, A; Nagai, Y; Ohmori, S; Ohta, A; Sada, Y; Tanaka, Y | 1 |
| Matsuura, K; Mori, Y; Nakamura, A; Utsunomiya, K; Yokoyama, J | 1 |
| Kaku, H; Tajiri, Y; Yamada, K | 1 |
| Schnell, O; Standl, E | 1 |
| Fujii, M; Ichikawa, M; Imagawa, M; Inaba, S; Kimura, T; Konoshita, T; Miyamori, I; Sato, S; Suzuki, J; Takahashi, S; Zenimaru, Y | 1 |
| Higa, M; Masuzaki, H; Sata, M; Shimabukuro, M; Yamakawa, K | 1 |
| Fujita, Y; Funahashi, T; Imagawa, A; Iwahashi, H; Kaneto, H; Kitamura, T; Kobayashi, Y; Kozawa, J; Maeda, N; Okita, K; Otsuki, M; Sasaki, S; Shimomura, I; Tamada, D; Yasuda, T | 1 |
| Aoki, C; Aso, Y; Niitani, M; Satoh, H; Suzuki, K; Yanagi, K | 1 |
| Fuchigami, M; Furuta, S; Hamada, Y; Nagasaki, H; Nakamura, J; Oiso, Y; Seino, Y | 1 |
| Bhatia, G; Chaturvedi, U; Saxena, JK; Shrivastava, A; Singh, SV | 1 |
| Barker, MK; Rose, DR | 1 |
| Ishibashi, S; Kotani, K; Nagashima, S; Okada, K; Osuga, J; Ozaki, K; Takahashi, M; Yagyu, H; Yamazaki, H | 1 |
| Alonzi, DS; Becq, F; Best, D; Blériot, Y; Butters, TD; Fleet, GW; Jenkinson, SF; Kato, A; Kunimatsu, T; Martínez, RF; Mui, J; Nakagawa, S; Norez, C; Saville, AW; Weymouth-Wilson, AC; Wilson, FX | 1 |
| Anno, T; Hashiramoto, M; Hirukawa, H; Kaku, K; Kanda-Kimura, Y; Kawasaki, F; Kimura, T; Matsuki, M; Mune, T; Shimoda, M; Tatsumi, F; Tawaramoto, K | 1 |
| Chiku, M; Fukamachi, D; Hirayama, A; Hiro, T; Kitano, D; Li, Y; Okumura, Y; Saito, S; Takayama, T | 1 |
| Fujita, Y; Hiraga, H; Kikuchi, O; Kim, HJ; Kitamura, T; Kitazumi, T; Kobayashi, M; Maruyama, J; Nakagawa, Y; Okamatsu-Ogura, Y; Saito, M; Sasaki, T; Shibata, H; Shimpuku, M; Susanti, VY; Yokota-Hashimoto, H | 1 |
| Abe, H; Fujitani, Y; Hara, A; Ishibashi, K; Kanazawa, A; Kawamori, R; Komiya, K; Ogihara, T; Tamaki, M; Uchida, T; Watada, H | 1 |
| Goda, T; Harazaki, T; Imai, C; Inoue, S; Mochizuki, K | 2 |
| Kim, SS; Koide, M; Nagasawa, Y; Sawada, T; Shiotani, H; Terashita, D; Yokoyama, M | 1 |
| Chae, SW; Choi, HG; Im, YJ; Jang, H; Jeon, JY; Kang, S; Kim, KH; Kim, MG; Kim, Y; Lee, SY | 1 |
| Aoki, K; Kamiko, K; Kamiyama, H; Masuda, K; Noguchi, Y; Tajima, K; Terauchi, Y | 1 |
| Hanaoka, H; Hashimoto, N; Ishikawa, K; Kanatsuka, A; Kobayashi, K; Kuribayashi, N; Onishi, S; Sakurai, K; Sato, Y; Takemoto, M; Terano, T; Uchida, D; Yokoh, H; Yokote, K | 1 |
| Fuchigami, M; Goda, T; Imai, C; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Jingu, S; Kinoshita, K; Mizuno-Yasuhira, A; Yamaguchi, J | 1 |
| Gunji, E; Jingu, S; Kinoshita, K; Mizuno-Yasuhira, A; Nakai, Y; Sakai, S; Samukawa, Y; Takahashi, T; Uchida, S; Yamaguchi, J | 1 |
| Fuchigami, M; Goda, T; Hariya, N; Inoue, S; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Murohashi, Y; Okazaki, N; Okuyama, T; Shirakawa, J; Tamura, T; Terauchi, Y; Togashi, Y; Yamazaki, S | 1 |
| Horikawa, Y; Mikada, A; Narita, T; Tsukiyama, K; Yamada, Y; Yamashita, R; Yokoyama, H | 1 |
| Anzai, N; Jomori, T; Jutabha, P; Kaneko, S; Lee, EY; Miki, T; Seino, S; Zhang, X | 1 |
| Adachi, I; Asano, N; Cha, JK; Fleet, GW; Hirokami, Y; Hollinshead, J; Kato, A; Kiappes, JL; Kinami, K; Miyawaki, S; Molyneux, RJ; Nash, RJ; Tsuji, Y; Zitzmann, N | 1 |
| Bahtiyar, G; Ezeji, GC; Inoue, T; Sacerdote, A | 1 |
| Hiraga, H; Kitamura, T; Sasaki, T; Yokota-Hashimoto, H | 1 |
| Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M | 1 |
| Chavan, SR; Dhavale, DD; Gavale, KS; Joshi, R; Khan, A | 1 |
| Asamoto, H; Nobushi, Y; Oi, T; Uchikura, K | 1 |
| Fukase, H; Harigai, M; Iida, S; Ikeda, S; Kasahara, N; Miyata, K; Ohba, Y; Saito, T; Takano, Y; Terao, K | 1 |
| Aoki, K; Shibata, E; Taguri, M; Tajima, K; Terauchi, Y | 1 |
| Hirose, S; Iwahashi, Y; Seo, A; Sumiyoshi, M; Takahashi, T; Tamori, Y | 1 |
| Sun, C; Wang, L; Yin, Q | 1 |
| Goto, M; Hariya, N; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Bauerfeind, MA; Chriqui, D; Engelke, T; Eom, SH; Goetz, M; González, MC; Großkinsky, DK; Guivarćh, A; Hirsche, J; Hyun, TK; Roitsch, T | 1 |
| Babu, RJ; Dash, RP; Srinivas, NR | 1 |
| Kishida, Y; Ohno, H; Oki, K; Okubo, H; Yoneda, M | 1 |
| Dong, YS; Ma, BP; Sang, YB; Sun, WL; Xiu, ZL; Yu, HS; Zhang, BW | 1 |
| Arasaki, O; Dai, K; Ikenaga, H; Inoue, Y; Ishihara, M; Kishimoto, S; Mori, Y; Niki, T; Node, K; Ogasawara, K; Oshiro, K; Sata, M; Shibata, Y; Shimabukuro, M; Takashima, A; Tanaka, A | 1 |
| Jedrzejczak, RP; Joachimiak, A; Tan, K; Tesar, C; Wilton, R | 1 |
| Fujimoto, K; Furusawa, K; Jomori, T; Kimura, I; Lee, EY; Miki, T; Miyamoto, J; Taknaka, T; Uematsu, S; Zhang, X | 1 |
| Bu, JL; Hu, ZC; Ke, X; Wang, RY; Zheng, YG | 1 |
| Iwasa, M; Kanamori, H; Kawaguchi, T; Kawasaki, M; Mikami, A; Minatoguchi, S; Naruse, G; Nishigaki, K; Yamada, Y; Yoshida, A | 1 |
| Fukui, K; Hatano, A; Kanno, Y; Kondo, Y; Sunaga, Y; Umezawa, H | 1 |
| Chen, L; Hu, ZC; Ke, X; Pan-Hong, Y; Sun, XQ; Zheng, YG | 1 |
| Davis, SN; Hedrington, MS | 1 |
| Li, D; Li, XM; Xu, PS; Xu, SM; Xu, YY; Yan, J | 1 |
| Li, M; Li, XL; Liu, YX; Peng, YT; Wang, KR; Yang, JX; Zhang, HX | 1 |
| D'Alonzo, D; Dechecchi, MC; Esposito, A; Fenza, M; Gregorio, E; Guaragna, A; Lippi, G; Tamanini, A | 1 |
| Guo, J; Hu, XL; Li, XM; Liu, WL; Xu, PS; Xu, SM; Xu, YY; Yan, J; Zhang, YX; Zou, T | 1 |
| Natori, Y | 1 |
| Doguchi, S; Hariya, N; Kondo, S; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Alssema, M; Blaak, EE; Dekker, JM; Denise Robertson, M; Dussort, P; Egli, L; Ruijgrok, C; Vinoy, S | 1 |
| Kaur, N; Kaur, P; Kumar, V; Nayak, SK; Sahu, SK; Wadhwa, P | 1 |
| Honda, Y; Imajo, K; Iwaki, M; Kessoku, T; Kobayashi, T; Nagashima, Y; Nakajima, A; Nogami, A; Ogawa, Y; Ozaki, A; Saito, S; Tomeno, W; Yoneda, M | 1 |
| Akbari, V; Bazdar, P; Goicoechea, HC; Jalalvand, AR; Khodarahmi, R | 1 |
| Donovan, CM; Jokiaho, AJ; Winchester, M | 1 |
| Bennett, JJ; Murphy, PV | 1 |
| Chen, J; Dong, LC; Fan, YX; He, JC; Wu, JL; Yu, CJ; Zhang, J; Zhang, P; Zhang, XP; Zhao, MX; Zhou, MD; Zhu, FJ | 1 |
27 review(s) available for 1-deoxynojirimycin and miglitol
| Article | Year |
|---|---|
alpha-Glucosidase inhibition in the treatment of diabetes mellitus.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Reference Values; Trisaccharides | 1992 |
[Inhibitors of alpha-glucosidase].
Topics: 1-Deoxynojirimycin; Acarbose; Blood Glucose; Carbohydrate Metabolism; Clinical Trials as Topic; Diabetes Mellitus; Digestion; Glucosamine; Glycoside Hydrolase Inhibitors; Imino Pyranoses; Insulin; Triglycerides; Trisaccharides | 1991 |
An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus.
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Animals; Blood Glucose; Carbohydrate Sequence; Contraindications; Diabetes Mellitus; Diabetic Nephropathies; Glucosamine; Glycogen; Glycogen Storage Disease; Glycoproteins; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Molecular Sequence Data; Sucrase-Isomaltase Complex; Trisaccharides | 1994 |
Alpha-glucosidase inhibition as an adjunct to the treatment of type 1 diabetes.
Topics: 1-Deoxynojirimycin; Acarbose; Blood Glucose; Diabetes Mellitus, Type 1; Eating; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemia; Imino Pyranoses; Trisaccharides | 1993 |
Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Body Weight; Cognition; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glucose Intolerance; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Trisaccharides | 1998 |
Type 2 diabetes: glycemic targets and oral therapies for older patients.
Topics: 1-Deoxynojirimycin; Acarbose; Age Factors; Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Metformin; Piperidines; Sulfonylurea Compounds; Trisaccharides | 1998 |
Drug therapy of postprandial hyperglycaemia.
Topics: 1-Deoxynojirimycin; Acarbose; Amyloid; Carbamates; Diabetes Mellitus; Enzyme Inhibitors; Glucosamine; Glyburide; Humans; Hyperglycemia; Hypoglycemic Agents; Imino Pyranoses; Inositol; Insulin; Insulin Lispro; Islet Amyloid Polypeptide; Piperidines; Postprandial Period; Trisaccharides | 1999 |
[Current status of the treatment of type 2 diabetes mellitus. Alpha-glucosidase inhibitors].
Topics: 1-Deoxynojirimycin; Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Disaccharides; Drug Combinations; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hydrolysis; Hypoglycemic Agents; Imino Pyranoses; Insulin; Polysaccharides | 1999 |
Oral pharmacologic management of type 2 diabetes.
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Metformin; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; United States | 1999 |
Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Glucosamine; Glucosidases; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Intestinal Absorption; Liver; Postprandial Period; Randomized Controlled Trials as Topic; Tissue Distribution | 2000 |
Improving management of type 2 diabetes mellitus: 1. alpha-Glucosidase inhibitors.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Imino Pyranoses | 1999 |
Miglitol: assessment of its role in the treatment of patients with diabetes mellitus.
Topics: 1-Deoxynojirimycin; Aged; Animals; Diabetes Mellitus; Drug Administration Schedule; Drug Interactions; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Intestinal Absorption; Middle Aged; Randomized Controlled Trials as Topic | 2000 |
Miglitol, a new alpha-glucosidase inhibitor.
Topics: 1-Deoxynojirimycin; Animals; Clinical Trials as Topic; Diabetes Mellitus; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses | 1999 |
[Reducing postprandial glucose levels. Glucosidase antagonists].
Topics: 1-Deoxynojirimycin; Acarbose; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glucosidases; Humans; Hypoglycemic Agents; Imino Pyranoses; Postprandial Period | 2002 |
Biochemistry and biotechnological applications of Gluconobacter strains.
Topics: 1-Deoxynojirimycin; Acetic Acid; Ascorbic Acid; Biotechnology; Carbohydrate Metabolism; Genome, Bacterial; Gluconates; Gluconobacter; Glucosamine; Hydrogen-Ion Concentration; Imino Pyranoses | 2002 |
Therapeutic options for the management of type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Diabetes Mellitus, Type 2; Disease Management; Education, Medical, Continuing; Education, Pharmacy, Continuing; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Aspart; Managed Care Programs; Metformin; Thiazoles; Thiazolidinediones; United States | 2002 |
Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Inositol; Randomized Controlled Trials as Topic | 2003 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2003 |
Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Inositol; Randomized Controlled Trials as Topic | 2005 |
[Adverse effects of alpha-glucosidase inhibitors].
Topics: 1-Deoxynojirimycin; Acarbose; Digestive System Diseases; Drug Interactions; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hyperammonemia; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Inositol | 2007 |
Pneumatosis cystoides intestinalis induced by the α-glucosidase inhibitor miglitol.
Topics: 1-Deoxynojirimycin; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Male; Middle Aged; Pneumatosis Cystoides Intestinalis | 2010 |
Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation.
Topics: 1-Deoxynojirimycin; Acarbose; Cardiovascular Diseases; Diabetes Complications; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol | 2012 |
Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Metformin; Prediabetic State | 2019 |
Synthesis and Therapeutic Applications of Iminosugars in Cystic Fibrosis.
Topics: 1-Deoxynojirimycin; Anti-Inflammatory Agents; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Glycoside Hydrolases; Glycosyltransferases; Heterocyclic Compounds, 1-Ring; Humans; Imino Pyranoses; Inflammation; Molecular Structure; Mutation; Sequence Deletion; Tartrates | 2020 |
[Synthesis of L-Iminofuranoses and Their Biological Evaluations].
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Diabetes Mellitus; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Structure-Activity Relationship | 2021 |
Effects of alpha-glucosidase-inhibiting drugs on acute postprandial glucose and insulin responses: a systematic review and meta-analysis.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus; Glucose; Glycoside Hydrolase Inhibitors; Humans; Inositol; Insulin; Postprandial Period | 2021 |
Alpha-amylase as molecular target for treatment of diabetes mellitus: A comprehensive review.
Topics: 1-Deoxynojirimycin; Acarbose; alpha-Amylases; Benzofurans; Blood Glucose; Diabetes Mellitus; Drug Discovery; Flavonoids; Glycoside Hydrolase Inhibitors; Humans; Hydrazones; Hypoglycemic Agents; Indoles; Inositol; Oxadiazoles; Structure-Activity Relationship | 2021 |
85 trial(s) available for 1-deoxynojirimycin and miglitol
| Article | Year |
|---|---|
Effects of alpha-glucosidase inhibitors on mouth to caecum transit time in humans.
Topics: 1-Deoxynojirimycin; Acarbose; Adolescent; Adult; Breath Tests; Gastrointestinal Transit; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hydrogen; Imino Pyranoses; Male; Stimulation, Chemical; Time Factors; Trisaccharides | 1992 |
alpha-Glucosidase inhibition by miglitol in NIDDM patients.
Topics: 1-Deoxynojirimycin; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary Carbohydrates; Fatty Acids, Nonesterified; Female; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Male; Middle Aged | 1992 |
[Delayed absorption of carbohydrates in the therapy of Type II diabetes: comparison between dietary (Muesli) and pharmacological (Alpha-glucosidase inhibition) modification].
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary Carbohydrates; Dietary Fiber; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Intestinal Absorption; Middle Aged | 1991 |
Inhibition of glycemic and hormonal responses after repetitive sucrose and starch loads by different doses of the alpha-glucosidase inhibitor miglitol (BAY m 1099) in man.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Dietary Carbohydrates; Double-Blind Method; Gastric Inhibitory Polypeptide; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Male; Starch; Sucrose | 1991 |
Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.
Topics: 1-Deoxynojirimycin; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diet, Diabetic; Eating; Female; Fructosamine; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Hexosamines; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin, Long-Acting; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Reference Values; Time Factors; Triglycerides | 1991 |
Effects of alpha-glucosidase inhibition and viscous fibre on diabetic control and postprandial gut hormone responses.
Topics: 1-Deoxynojirimycin; Adult; Aged; Biomarkers; Blood Glucose; Cholesterol; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dietary Fiber; Double-Blind Method; Eating; Female; Fructosamine; Galactans; Glucosamine; Glycoside Hydrolase Inhibitors; Hexosamines; Humans; Imino Pyranoses; Male; Mannans; Middle Aged; Plant Gums; Random Allocation; Triglycerides | 1990 |
The acute effects of glucosidase inhibition on post-meal glucose increments in insulin-dependent diabetics.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Male; Middle Aged; Randomized Controlled Trials as Topic; Time Factors | 1990 |
The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism?
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Adult; Blood Glucose; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Male; Trisaccharides | 1990 |
The effect of short chain fatty acid supplementation on membrane electrolyte transport and blood pressure.
Topics: 1-Deoxynojirimycin; Adult; Biological Transport; Blood Pressure; Double-Blind Method; Electrolytes; Erythrocyte Membrane; Erythrocytes; Fatty Acids, Volatile; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Linoleic Acid; Linoleic Acids; Male; Oleic Acid; Oleic Acids; Palmitic Acids; Potassium; Sodium | 1990 |
Postprandial glycemic control, hormonal effects and carbohydrate malabsorption during long-term administration of the alpha-glucosidase inhibitor miglitol.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Breath Tests; Dietary Carbohydrates; Double-Blind Method; Gastric Inhibitory Polypeptide; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hydrogen; Imino Pyranoses; Insulin; Malabsorption Syndromes; Male; Time Factors | 1990 |
Effect of alpha-glucosidase inhibition on glucose profiles in insulin dependent diabetes.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 1; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Middle Aged; Triglycerides | 1989 |
Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Liver; Male; Middle Aged | 1989 |
Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Dose-Response Relationship, Drug; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Middle Aged; Time Factors | 1989 |
Alpha glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Intestinal Absorption; Middle Aged; Random Allocation | 1988 |
Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo.
Topics: 1-Deoxynojirimycin; 3-Hydroxybutyric Acid; Alanine; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Eating; Fatty Acids, Nonesterified; Female; Glucosamine; Glycerol; Glycoside Hydrolase Inhibitors; Humans; Hydroxybutyrates; Hypoglycemic Agents; Imino Pyranoses; Insulin; Lactates; Male; Middle Aged; Pyruvates | 1988 |
Intestinal and metabolic responses to an alpha-glucosidase inhibitor in normal volunteers.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Breath Tests; Feces; Female; Gastric Inhibitory Polypeptide; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hydrogen; Imino Pyranoses; Insulin; Intestinal Mucosa; Intestines; Male | 1988 |
Effects of prolonged administration of two new alpha-glucosidase inhibitors on blood glucose control, insulin requirements and breath hydrogen excretion in patients with insulin-dependent diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Anti-Bacterial Agents; Blood Glucose; Breath Tests; Diabetes Mellitus, Type 1; Drug Administration Schedule; Glucosamine; Humans; Hydrogen; Imino Pyranoses; Insulin; Male | 1988 |
Effect of two new alpha-glucosidase inhibitors in insulin-dependent diabetic patients.
Topics: 1-Deoxynojirimycin; Adult; Diabetes Mellitus, Type 1; Diet; Double-Blind Method; Female; Glucosamine; Glucosidases; Humans; Hyperglycemia; Hypoglycemia; Imino Pyranoses; Insulin; Male; Random Allocation | 1988 |
A new alpha-glucosidase inhibitor (Bay-m-1099) reduces insulin requirements with meals in insulin-dependent diabetes mellitus.
Topics: 1-Deoxynojirimycin; Anti-Bacterial Agents; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Dietary Carbohydrates; Eating; Female; Glucosamine; Humans; Imino Pyranoses; Insulin; Male; Random Allocation | 1987 |
Assessment of the clinical efficacy and tolerance of two new alpha-glucosidase inhibitors in insulin-treated diabetics.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Body Weight; Diabetes Mellitus; Drug Tolerance; Fatty Acids, Nonesterified; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Male; Middle Aged | 1987 |
The effect of two new alpha-glucosidase inhibitors on metabolic responses to a mixed meal in normal volunteers.
Topics: 1-Deoxynojirimycin; Adult; Anti-Bacterial Agents; Blood Glucose; Female; Food; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Male; Triglycerides | 1987 |
The effect of new alpha-glucosidase inhibitors (BAY m 1099 and BAY o 1248) on meal-stimulated increases in glucose and insulin levels in man.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Clinical Trials as Topic; Dose-Response Relationship, Drug; Glucosamine; Glucosidases; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Male; Middle Aged; Random Allocation | 1986 |
Effect of alpha-glycohydrolase inhibitors (Bay m1099 and Bay o1248) on sucrose metabolism in normal men.
Topics: 1-Deoxynojirimycin; Administration, Oral; Adult; Blood Glucose; Breath Tests; Fatty Acids, Nonesterified; Glucosamine; Humans; Hydrogen; Imino Pyranoses; Insulin; Lipids; Male; Pulmonary Gas Exchange; Sucrose | 1986 |
Effects of two new alpha-glucosidase inhibitors on glycemic control in patients with insulin-dependent diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Breath Tests; Clinical Trials as Topic; Deuterium; Diabetes Mellitus, Type 1; Double-Blind Method; Glucosamine; Humans; Imino Pyranoses; Insulin; Insulin Infusion Systems; Male; Random Allocation | 1986 |
Effects of the alpha-glucosidase inhibitor 1 desoxynojirimycin (Bay m 1099) on postprandial blood glucose, serum insulin and C-peptide levels in type II diabetic patients.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Eating; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Male; Middle Aged; Obesity; Pancreatic Hormones | 1986 |
A double-blind study on the efficacy and tolerance of a new alpha-glucosidase inhibitor in type-2 diabetics.
Topics: 1-Deoxynojirimycin; Adult; Aged; Anti-Bacterial Agents; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Tolerance; Female; Glucosamine; Humans; Imino Pyranoses; Male; Middle Aged; Random Allocation | 1986 |
Smoothing effect of a new alpha-glucosidase inhibitor BAY m 1099 on blood glucose profiles of sulfonylurea-treated type II diabetic patients.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Male; Middle Aged; Sulfonylurea Compounds | 1986 |
[Miglitol in the treatment of the insulin-dependent diabetic patient. Improved metabolic control and excellent tolerance].
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Glucosamine; Glycated Hemoglobin; Humans; Imino Pyranoses | 1987 |
Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Enzyme Inhibitors; Female; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Male; Middle Aged; Multivariate Analysis; Time Factors; Treatment Failure; Triglycerides | 1995 |
Effect of miglitol (BAY m-1099) on fasting blood glucose in type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Male; Middle Aged | 1994 |
Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients.
Topics: 1-Deoxynojirimycin; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Lipids; Male; Middle Aged; Time Factors | 1994 |
Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
Topics: 1-Deoxynojirimycin; Biomarkers; Blood Glucose; Cholesterol; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Enzyme Inhibitors; Female; Fructosamine; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Male; Metabolic Clearance Rate; Middle Aged; Triglycerides | 1996 |
Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males.
Topics: 1-Deoxynojirimycin; Adult; Anticoagulants; Blood Coagulation; Cross-Over Studies; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Glucosamine; Glucosidases; Humans; Imino Pyranoses; Male; Stereoisomerism; Warfarin | 1996 |
Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers.
Topics: 1-Deoxynojirimycin; Adult; Area Under Curve; Blood Glucose; C-Peptide; Double-Blind Method; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Intestine, Small; Male; Placebos | 1996 |
The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diarrhea; Diet, Diabetic; Double-Blind Method; Enzyme Inhibitors; Fasting; Female; Flatulence; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Male; Middle Aged; Placebos; Postprandial Period | 1997 |
Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man.
Topics: 1-Deoxynojirimycin; Administration, Oral; Animals; Autoradiography; Blood Proteins; Dogs; Duodenum; Enzyme Inhibitors; Feces; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Injections, Intravenous; Male; Milk; Placenta; Pregnancy; Protein Binding; Rats; Rats, Sprague-Dawley; Rats, Wistar; Species Specificity; Tissue Distribution | 1997 |
Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
Topics: 1-Deoxynojirimycin; Albuminuria; Blood Glucose; Creatinine; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Enzyme Inhibitors; Female; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Hispanic or Latino; Humans; Imino Pyranoses; Insulin; Lipids; Male; Middle Aged; Placebos; Postprandial Period; Time Factors; Treatment Outcome | 1998 |
Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
Topics: 1-Deoxynojirimycin; Black People; Blood Glucose; Cholesterol, LDL; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Enzyme Inhibitors; Female; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Male; Middle Aged; Placebos; Postprandial Period; Single-Blind Method; Sulfonylurea Compounds; Treatment Outcome; Triglycerides | 1998 |
Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Enzyme Inhibitors; Fasting; Female; Food; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Kinetics; Male | 1998 |
Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Enzyme Inhibitors; Fasting; Female; Follow-Up Studies; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Male; Middle Aged; Postprandial Period; Time Factors | 1998 |
[Alpha-glucosidase inhibitor for type 2 diabetic patients. Clinical study with miglitol].
Topics: 1-Deoxynojirimycin; Diabetes Mellitus, Type 2; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin Resistance | 2000 |
Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics.
Topics: 1-Deoxynojirimycin; Analysis of Variance; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Drug Therapy, Combination; Female; Glucosamine; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Male; Metformin; Middle Aged; Placebos | 2001 |
The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes.
Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Fasting; Female; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Male; Metformin; Middle Aged; Placebos; Postprandial Period; Racial Groups | 2001 |
Miglitol combined with metformin improves glycaemic control in type 2 diabetes.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Male; Metformin; Middle Aged; Single-Blind Method | 2001 |
Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Food; Gastrointestinal Diseases; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Male; Middle Aged; Placebos | 2002 |
The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Topics: 1-Deoxynojirimycin; Adult; Aged; Appetite; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Middle Aged; Obesity; Peptide Fragments; Postprandial Period; Protein Precursors | 2002 |
HbA(1c) and glycemic profile, basal- and post-treatment with Miglitol, in an area with a Mediterranean diet.
Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Diet, Diabetic; Fasting; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Mediterranean Region; Postprandial Period; Regression Analysis | 2002 |
Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adiponectin; Albuminuria; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Imino Pyranoses; Male; Middle Aged | 2007 |
Divided-dose administration of miglitol just before and 15 minutes after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men.
Topics: 1-Deoxynojirimycin; Administration, Oral; Adult; Area Under Curve; Blood Glucose; Cross-Over Studies; Drug Administration Schedule; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Male; Postprandial Period | 2007 |
Evaluation of the efficacy, safety and tolerability of miglitol in adult Indian patients with uncomplicated type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Imino Pyranoses; India; Male; Middle Aged; Postprandial Period; Prospective Studies; Risk Factors; Treatment Outcome | 2007 |
Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
Topics: 1-Deoxynojirimycin; Acarbose; Adult; Blood Glucose; Cross-Over Studies; Enzyme Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Insulin; Intercellular Adhesion Molecule-1; Interleukin-6; Lipids; Lipoprotein Lipase; Male; Middle Aged; Obesity; Postprandial Period; Single-Blind Method; Vascular Cell Adhesion Molecule-1; Viscera | 2008 |
Comparison of pre- vs. postmeal administration of miglitol for 3 months in type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Analysis of Variance; Biomarkers; Deoxyglucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Postprandial Period | 2008 |
Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance.
Topics: 1-Deoxynojirimycin; Aged; Benzamides; Cystatin C; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged | 2009 |
Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Food; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Insulin; Kinetics; Male; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Cross-Over Studies; Enzyme Inhibitors; Fasting; Food; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Kinetics; Male | 2010 |
Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic p
Topics: 1-Deoxynojirimycin; Aged; Coronary Artery Disease; Coronary Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Female; Glucose; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Inositol; Lipid Metabolism; Male; Middle Aged; Treatment Outcome | 2010 |
Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: a crossover study.
Topics: 1-Deoxynojirimycin; Acarbose; Adult; Cross-Over Studies; Gastrointestinal Agents; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Male | 2010 |
Efficacy of combined use of miglitol in Type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Postprandial Period | 2011 |
Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; China; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sulfonylurea Compounds | 2011 |
Comparing the efficacy of α-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study.
Topics: 1-Deoxynojirimycin; Acarbose; Adult; Aged; alpha-Glucosidases; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Japan; Male; Middle Aged; Pilot Projects; Young Adult | 2011 |
Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Aged; Deoxyglucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Enzyme Inhibitors; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Male; Middle Aged; Serum Albumin; Weight Loss; Young Adult | 2011 |
Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Food-Drug Interactions; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Asian People; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Inositol; Male; Middle Aged; Obesity; Postprandial Period | 2012 |
Effect of miglitol as an add-on to bolus insulin on postprandial glycemic excursions in type 2 diabetes patients assessed by continuous glucose monitoring.
Topics: 1-Deoxynojirimycin; Adult; Aged; Area Under Curve; Blood Glucose; Blood Glucose Self-Monitoring; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Male; Middle Aged; Postprandial Period; Prospective Studies; Treatment Outcome; Young Adult | 2012 |
Anorexigenic effects of miglitol in concert with the alterations of gut hormone secretion and gastric emptying in healthy subjects.
Topics: 1-Deoxynojirimycin; Adult; Appetite; Appetite Depressants; Female; Gastric Emptying; Ghrelin; Glucagon-Like Peptide 1; Humans; Male; Obesity; Peptide YY; Young Adult | 2012 |
Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.
Topics: 1-Deoxynojirimycin; Apolipoprotein A-I; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin Lispro; Lipids; Lipoproteins, HDL; Male; Middle Aged; Postprandial Period; Treatment Outcome; Triglycerides | 2012 |
Miglitol, α-glycosidase inhibitor, reduces visceral fat accumulation and cardiovascular risk factors in subjects with the metabolic syndrome: a randomized comparable study.
Topics: 1-Deoxynojirimycin; Adult; alpha-Glucosidases; Cardiovascular Diseases; Female; Glycoside Hydrolase Inhibitors; Humans; Intra-Abdominal Fat; Male; Metabolic Syndrome; Middle Aged; Obesity; Risk Factors; Risk Reduction Behavior | 2013 |
Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Fasting; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Isoindoles; Male; Metformin; Middle Aged; Prognosis | 2013 |
Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia.
Topics: 1-Deoxynojirimycin; Acute Coronary Syndrome; Aged; Case-Control Studies; Endothelium, Vascular; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Manometry; Middle Aged; Percutaneous Coronary Intervention; Postprandial Period; Treatment Outcome | 2013 |
Comparison of effects of α-Glucosidase inhibitors and glinide drugs on endothelial dysfunction in diabetic patients with coronary artery disease.
Topics: 1-Deoxynojirimycin; Aged; Aged, 80 and over; Coronary Artery Disease; Cyclohexanes; Diabetic Angiopathies; Dyslipidemias; Endothelium, Vascular; Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Nateglinide; Phenylalanine | 2014 |
Pharmacokinetic comparisons between two formulations containing 100 mg of miglitol in healthy male Korean volunteers: a randomized, open-label, single-dose, two-period, two-sequence crossover bioequivalence study.
Topics: 1-Deoxynojirimycin; Adult; Area Under Curve; Biological Availability; Chemistry, Pharmaceutical; Cross-Over Studies; Glycoside Hydrolase Inhibitors; Healthy Volunteers; Humans; Hypoglycemic Agents; Korea; Male; Tandem Mass Spectrometry; Therapeutic Equivalency | 2014 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-i
Topics: 1-Deoxynojirimycin; Aged; alpha-Glucosidases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastrointestinal Agents; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Inositol; Japan; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2014 |
Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
Topics: 1-Deoxynojirimycin; Adult; Aged; Asian People; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; E-Selectin; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Interleukin-8; Japan; Male; Middle Aged; Prospective Studies; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vascular Cell Adhesion Molecule-1 | 2014 |
Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Asian People; Blood Glucose; Cardiovascular Diseases; Chemokine CCL2; Diabetes Mellitus, Type 2; Drug Therapy, Combination; E-Selectin; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Middle Aged; Prospective Studies; Risk Factors; Time Factors | 2014 |
Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial".
Topics: 1-Deoxynojirimycin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Incretins; Intra-Abdominal Fat; Japan; Male; Middle Aged; Overweight; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2014 |
Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.
Topics: 1-Deoxynojirimycin; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Female; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sorbitol; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2015 |
A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Topics: 1-Deoxynojirimycin; Adult; Benzhydryl Compounds; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Urine; Young Adult | 2016 |
Comparison of efficacy and safety of taking miglitol dissolved in water during a meal and taking a miglitol tablet just before a meal in patients with type 2 diabetes.
Topics: 1-Deoxynojirimycin; Blood Glucose; Breakfast; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Postprandial Period; Tablets | 2016 |
Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Leptin; Male; Metformin; Middle Aged; Pyrimidines; Treatment Outcome | 2016 |
α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study.
Topics: 1-Deoxynojirimycin; Acute Coronary Syndrome; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Glycoside Hydrolase Inhibitors; Heart Rate; Humans; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome | 2017 |
Validation of the ADVIA Centaur® XP system for the determination of insulin and its application.
Topics: 1-Deoxynojirimycin; Adult; Cross-Over Studies; Female; Healthy Volunteers; Humans; Hypoglycemic Agents; Immunoassay; Insulin; Luminescent Measurements; Male; Therapeutic Equivalency; Young Adult | 2020 |
Bioequivalence and Evaluation Parameters Based on the Pharmacodynamics of Miglitol in Healthy Volunteers.
Topics: 1-Deoxynojirimycin; Adult; Area Under Curve; Blood Glucose; Cross-Over Studies; Female; Humans; Hypoglycemic Agents; Male; Therapeutic Equivalency; Young Adult | 2021 |
S100 Genes are Highly Expressed in Peripheral Leukocytes of Type 2 Diabetes Mellitus Patients Treated with Dietary Therapy.
Topics: 1-Deoxynojirimycin; Adult; Aged; Cytokines; Diabetes Mellitus, Type 2; Fasting; Female; Gene Expression Regulation; Hospitals, University; Humans; Hypoglycemic Agents; Inflammation; Leukocytes; Male; Middle Aged; Prospective Studies; RNA, Messenger; S100 Proteins | 2021 |
Bioequivalence Study of Miglitol Orally Disintegrating Tablets in Healthy Chinese Volunteers Under Fasting Condition Based on Pharmacodynamic and Pharmacokinetic Parameters.
Topics: 1-Deoxynojirimycin; Area Under Curve; East Asian People; Fasting; Healthy Volunteers; Humans; Sucrose; Tablets; Tandem Mass Spectrometry; Therapeutic Equivalency | 2023 |
115 other study(ies) available for 1-deoxynojirimycin and miglitol
| Article | Year |
|---|---|
New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii.
Topics: Alkaloids; Animals; Cameroon; Carbohydrates; Cattle; Coffee; Enzyme Inhibitors; Fabaceae; Glucan 1,4-alpha-Glucosidase; Glycoside Hydrolases; Intestines; Liver; Molecular Conformation; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Oryza; Plant Bark; Plants, Medicinal; Rats; Stereoisomerism; Structure-Activity Relationship; Yeasts | 2002 |
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
Topics: Animals; Caco-2 Cells; Carbohydrate Conformation; Cells, Cultured; Dose-Response Relationship, Drug; Fibroblasts; Gaucher Disease; Glycogen; Glycoside Hydrolases; Hepatocytes; Humans; Imino Sugars; Lysosomes; Rats; Structure-Activity Relationship | 2008 |
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
Topics: Absorption; Animals; Blood Glucose; Carbohydrate Metabolism; Glycated Hemoglobin; Glycosphingolipids; Imino Sugars; Mice; Mice, Obese; Obesity; Rats; Rats, Zucker; Structure-Activity Relationship; Viscera | 2010 |
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
Topics: Administration, Oral; Animals; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Imino Sugars; Inhibitory Concentration 50; Male; Mice; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2012 |
Synthesis and characterization of novel, conjugated, fluorescent DNJ derivatives for α-glucosidase recognition.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Cell Membrane; Dose-Response Relationship, Drug; Fluorescent Dyes; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship | 2017 |
The effects of low-dose Bay-m-1099 (Miglitol) on serum lipids and liver enzyme activity of obese and obese-diabetic corpulent rats.
Topics: 1-Deoxynojirimycin; Adipose Tissue; Animals; Blood Glucose; Blood Proteins; Diabetes Mellitus; Glucokinase; Glucosamine; Glucosephosphate Dehydrogenase; Glycoside Hydrolase Inhibitors; Imino Pyranoses; Insulin; Lipids; Liver; Obesity; Phenotype; Rats; Weight Gain | 1991 |
Lysosomal storage of glycogen as a sequel of alpha-glucosidase inhibition by the absorbed deoxynojirimycin derivative emiglitate (BAYo1248). A drug-induced pattern of hepatic glycogen storage mimicking Pompe's disease (glycogenosis type II).
Topics: 1-Deoxynojirimycin; Acarbose; Animals; Female; Glucosamine; Glycogen Storage Disease Type II; Glycoside Hydrolase Inhibitors; Imino Pyranoses; Liver; Liver Glycogen; Lysosomes; Microscopy, Electron; Rats; Rats, Inbred Strains; Trisaccharides | 1991 |
[Inhibitor of carbohydrate metabolism (inhibitor of gluconeogenesis, disaccharidase inhibitor)].
Topics: 1-Deoxynojirimycin; 3-Mercaptopropionic Acid; Acarbose; Animals; Carbohydrate Metabolism; Cyclohexanols; Cycloserine; Disaccharidases; Gluconeogenesis; Glucosamine; Humans; Hydrazines; Imino Pyranoses; Liver; Oleic Acids; Trisaccharides | 1991 |
Effects of alpha-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type I diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Eating; Energy Intake; Glucosamine; Glucose Clamp Technique; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Male | 1991 |
Effect of the alpha-glucosidase inhibitor N-hydroxyethyl-1-deoxynojirimycin (Bay m 1099) on the biosynthesis of liver secretory glycoproteins.
Topics: 1-Deoxynojirimycin; Acetylglucosaminidase; alpha 1-Antitrypsin; Animals; Electrophoresis, Polyacrylamide Gel; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Imino Pyranoses; In Vitro Techniques; Liver; Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase; Orosomucoid; Precipitin Tests; Rats; Rats, Inbred Strains | 1989 |
Effects of N-hydroxyethyl-1-deoxynojirimycin (BAY m 1099) on the activity of neutral- and acid alpha-glucosidases in human fibroblasts and HepG2 cells.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Binding, Competitive; Carcinoma, Hepatocellular; Fibroblasts; Glucosamine; Glycogen; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Immunohistochemistry; Kinetics; Liver Neoplasms; Lysosomes; Microscopy, Electron; Molecular Weight; Tumor Cells, Cultured | 1989 |
Metabolic consequences of the alpha-glucosidase inhibitor BAY-M-1099 given to nondiabetic and diabetic rats fed a high-carbohydrate diet.
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diet; Dietary Carbohydrates; Glucosamine; Glycoside Hydrolase Inhibitors; Glycosuria; Imino Pyranoses; Male; Rats; Rats, Inbred Strains; Sucrose; Triglycerides | 1989 |
The effect of acarbose and miglitol (BAY-M-1099) on postprandial glucose levels following ingestion of various sources of starch by nondiabetic and streptozotocin-induced diabetic rats.
Topics: 1-Deoxynojirimycin; Acarbose; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Eating; Glucosamine; Glucose; Glucosidases; Imino Pyranoses; Insulin; Male; Rats; Starch; Trisaccharides | 1989 |
Inhibitory mechanism of acarbose and 1-deoxynojirimycin derivatives on carbohydrases in rat small intestine.
Topics: 1-Deoxynojirimycin; Acarbose; alpha-Amylases; Animals; Anti-Bacterial Agents; Female; Glucosamine; Glycoside Hydrolases; Hypoglycemic Agents; Imino Pyranoses; In Vitro Techniques; Intestine, Small; Kinetics; Microvilli; Pancreas; Rats; Rats, Inbred Strains; Trisaccharides | 1987 |
1-Deoxynojirimycin and related compounds inhibit glycogenolysis in the liver without affecting the concentration of phosphorylase a.
Topics: 1-Deoxynojirimycin; Animals; Dose-Response Relationship, Drug; Glucagon; Glucosamine; Glycogen Synthase; Glycoside Hydrolase Inhibitors; Imino Pyranoses; Liver; Liver Glycogen; Male; Phosphorylase a; Phosphorylases; Rats; Rats, Inbred Strains; Structure-Activity Relationship | 1988 |
Effect of alpha-inhibitors on blood glucose and insulin levels.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Middle Aged; Obesity; Reference Values; Trisaccharides | 1988 |
Alpha-glucosidase inhibition and timing of preprandial insulin in patients with insulin-dependent diabetes mellitus (IDDM).
Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 1; Drug Administration Schedule; Eating; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Kinetics; Male | 1988 |
Adaptive responses to pharmacological inhibition of small intestinal alpha-glucosidases in the rat.
Topics: 1-Deoxynojirimycin; Adaptation, Physiological; Animals; Cecum; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Imino Pyranoses; Intestine, Small; Organ Size; Polyamines; Rats; Rats, Inbred Strains | 1987 |
Effect of an alpha-glucosidase inhibitor (BAY m 1099) on post-prandial blood glucose and insulin in type II diabetics.
Topics: 1-Deoxynojirimycin; Adult; Aged; Anti-Bacterial Agents; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosamine; Humans; Imino Pyranoses; Insulin; Male; Middle Aged | 1986 |
Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha-glucosidase.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Male | 1987 |
Regulation of the absorption of dietary carbohydrate in man by two new glycosidase inhibitors.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Dietary Carbohydrates; Dose-Response Relationship, Drug; Glucosamine; Glycoside Hydrolases; Humans; Hydrogen; Imino Pyranoses; Intestinal Absorption; Male; Maltose; Starch; Substrate Specificity; Sucrose | 1986 |
Effect of 1-desoxynojirimycin derivatives on small intestinal disaccharidase activities and on active transport in vitro.
Topics: 1-Deoxynojirimycin; Alkaline Phosphatase; Animals; Anti-Bacterial Agents; Biological Transport, Active; Disaccharidases; Female; Glucosamine; Imino Pyranoses; In Vitro Techniques; Intestinal Mucosa; Intestine, Small; Leucine; Methylglucosides; Rats; Rats, Inbred Strains | 1985 |
Ca2+ deficiency, selective alpha-glucosidehydrolase inhibition, and insulin secretion.
Topics: 1-Deoxynojirimycin; 1-Methyl-3-isobutylxanthine; Animals; Calcium; Dose-Response Relationship, Drug; Female; Glucosamine; Glucose; Glycoside Hydrolase Inhibitors; Imino Pyranoses; Insulin; Insulin Secretion; Islets of Langerhans; Lysosomes; Mice; Mice, Inbred Strains; Mice, Mutant Strains; Muscular Dystrophy, Animal | 1993 |
The effects of the intestinal glucosidase inhibitory BAY M 1099 (miglitol) on glycemic status of obese-diabetic rats.
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Eating; Glucosamine; Glycoside Hydrolase Inhibitors; Imino Pyranoses; Male; Obesity; Rats; Rats, Inbred SHR | 1993 |
In vitro study of the effect of miglitol on carbohydrate digestion and intestinal metabolism in normal and non-insulin-dependent diabetic rats.
Topics: 1-Deoxynojirimycin; Animals; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosamine; Glycoside Hydrolase Inhibitors; Imino Pyranoses; In Vitro Techniques; Intestinal Absorption; Intestine, Small; Male; Perfusion; Rats; Rats, Wistar | 1996 |
Effect of miglitol administration to non-insulin-dependent diabetic rats.
Topics: 1-Deoxynojirimycin; Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Enzyme Inhibitors; Glucosamine; Hypoglycemic Agents; Imino Pyranoses; Male; Rats; Rats, Wistar | 1998 |
Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose.
Topics: 1-Deoxynojirimycin; Animal Feed; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Glucosamine; Glucose; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Secretion; Islets of Langerhans; Obesity; Rats; Rats, Sprague-Dawley; Ventromedial Hypothalamic Nucleus | 1999 |
Miglitol for type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Diabetes Mellitus, Type 2; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses | 1999 |
Glucose tolerance and insulin resistance in the JCR:LA-corpulent rat: effect of miglitol (Bay m1099).
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Body Weight; Disease Models, Animal; Eating; Enzyme Inhibitors; Glucosamine; Glucose Tolerance Test; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Resistance; Lipids; Male; Obesity; Postprandial Period; Rats | 1999 |
A novel anti-diabetic drug, miglitol, markedly reduces myocardial infarct size in rabbits.
Topics: 1-Deoxynojirimycin; Animals; Dose-Response Relationship, Drug; Glucosamine; Glycogen; Hemodynamics; Hypoglycemic Agents; Imino Pyranoses; Lactic Acid; Male; Myocardial Infarction; Myocardium; Rabbits | 1999 |
[Drug therapy of type 2 diabetes: insulin sensitizers improve results].
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Diet Therapy; Diet, Diabetic; Drug Therapy, Combination; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin | 1999 |
[Risk of complications in the diabetic patient. Postprandial blood glucose peaks as deciding factor].
Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses | 2000 |
Miglitol and hepatotoxicity in type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Liver; Liver Function Tests; Transaminases | 2000 |
Similarity in the linear and non-linear oral absorption of drugs between human and rat.
Topics: 1-Deoxynojirimycin; Acyclovir; Administration, Oral; Animals; Chlorothiazide; Glucosamine; Humans; Imino Pyranoses; Intestinal Absorption; Propanolamines; Rats; Species Specificity | 2000 |
A new era in type 2 diabetes mellitus treatment?
Topics: 1-Deoxynojirimycin; Acarbose; Carbamates; Diabetes Mellitus, Type 2; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Multicenter Studies as Topic; Pioglitazone; Piperidines; Randomized Controlled Trials as Topic; Thiazoles; Thiazolidinediones | 2001 |
Combination of miglitol, an anti-diabetic drug, and nicorandil markedly reduces myocardial infarct size through opening the mitochondrial K(ATP) channels in rabbits.
Topics: 1-Deoxynojirimycin; Adenosine Triphosphate; Animals; Anti-Arrhythmia Agents; Blood Pressure; Decanoic Acids; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucosamine; Heart Rate; Hemodynamics; Hydroxy Acids; Hypoglycemic Agents; Imino Pyranoses; Male; Mitochondria, Heart; Myocardial Infarction; Nicorandil; Potassium Channels; Rabbits | 2001 |
[Alpha-glucosidase inhibitor in type 2 diabetic patients. Metabolism and body weight are favorably modified].
Topics: 1-Deoxynojirimycin; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Energy Metabolism; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses | 2001 |
Potential pharmacokinetics interference between alpha-glucosidase inhibitors and other oral antidiabetic agents.
Topics: 1-Deoxynojirimycin; Administration, Oral; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Intestinal Absorption | 2002 |
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors | 2003 |
[Usefulness of miglitol in patients with diabetes mellitus type 2 and insufficient control of the blood glucose].
Topics: 1-Deoxynojirimycin; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glucosamine; Humans; Hyperlipidemias; Hypoglycemic Agents; Imino Pyranoses; Lipids; Male; Middle Aged; Treatment Outcome | 2004 |
Antidiabetic drug miglitol inhibits myocardial apoptosis involving decreased hydroxyl radical production and Bax expression in an ischaemia/reperfusion rabbit heart.
Topics: 1-Deoxynojirimycin; Animals; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blood Pressure; Blotting, Western; DNA Fragmentation; Electrophoresis, Agar Gel; Gentisates; Glucosamine; Heart Rate; Hemodynamics; Hydroxyl Radical; Hypoglycemic Agents; Imino Pyranoses; Immunohistochemistry; In Situ Nick-End Labeling; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Proto-Oncogene Proteins c-bcl-2; Rabbits; Time Factors | 2004 |
[Treatment of type 2 diabetes mellitus with the alpha-glucosidase inhibitor Miglitol in the doctor's office].
Topics: 1-Deoxynojirimycin; Adult; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Family Practice; Feasibility Studies; Female; Follow-Up Studies; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Internal Medicine; Male; Middle Aged; Patient Compliance; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Weight Loss | 2000 |
[The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office].
Topics: 1-Deoxynojirimycin; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Male; Middle Aged; Safety; Time Factors; Triglycerides | 2001 |
The anti-diabetic drug miglitol is protective against anginal ischaemia through a mechanism independent of regional myocardial blood flow in the dog.
Topics: 1-Deoxynojirimycin; Angina Pectoris; Animals; Blood Glucose; Blood Pressure; Coronary Circulation; Dogs; Glucosamine; Heart Rate; Hypoglycemic Agents; Imino Pyranoses; Lactates; Male; Myocardial Ischemia; Myocardium | 2005 |
[Pharmacokinetic, pharmacological, and clinical profile of miglitol (SEIBULE), a novel alpha-glucosidase inhibitor].
Topics: 1-Deoxynojirimycin; Animals; Diabetes Mellitus, Type 2; Dogs; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Rats | 2006 |
Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma.
Topics: 1-Deoxynojirimycin; Biological Availability; Chromatography, Liquid; Glucosamine; Half-Life; Humans; Hypoglycemic Agents; Imino Pyranoses; Magnetic Resonance Spectroscopy; Mass Spectrometry; Reproducibility of Results; Therapeutic Equivalency | 2006 |
Determination of miglitol in human plasma by liquid chromatography/tandem mass spectrometry.
Topics: 1-Deoxynojirimycin; Administration, Oral; Chromatography, High Pressure Liquid; Humans; Hypoglycemic Agents; Imino Pyranoses; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2007 |
Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule; Enzyme Inhibitors; Female; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Male; Middle Aged | 2007 |
Effects of miglitol, an alpha-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats.
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Diabetes Mellitus; Hypoglycemic Agents; Imino Pyranoses; Islets of Langerhans; Male; Random Allocation; Rats; Rats, Wistar; Treatment Outcome | 2007 |
[In-vitro study of the drug interactions between Miglitol, an alpha-glucosidase inhibitor, and adsorbents].
Topics: 1-Deoxynojirimycin; Adsorption; Carbohydrates; Carbon; Cation Exchange Resins; Cholestyramine Resin; Drug Interactions; Enzyme Inhibitors; Epichlorohydrin; Glycoside Hydrolase Inhibitors; Hydrogen-Ion Concentration; Hypoglycemic Agents; Imidazoles; Imino Pyranoses; In Vitro Techniques; Polyamines; Polystyrenes; Resins, Synthetic; Sevelamer | 2007 |
Synthesis of iminoalditol analogues of galactofuranosides and their activities against glycosidases.
Topics: 1-Deoxynojirimycin; Anti-Bacterial Agents; Enzyme Activation; Enzyme Inhibitors; Galactose; Glycoside Hydrolases; Glycosides; Humans; Hypoglycemic Agents; Models, Molecular; Sugar Alcohols | 2008 |
Effect of miglitol, an alpha-glucosidase inhibitor, on atherogenic outcomes in balloon-injured diabetic rats.
Topics: 1-Deoxynojirimycin; Animals; Atherosclerosis; Blood Glucose; Catheterization; Diabetes Mellitus, Experimental; Dietary Fats; Hypoglycemic Agents; Male; Rats; Rats, Wistar | 2009 |
Rapid quantification of miglustat in human plasma and cerebrospinal fluid by liquid chromatography coupled with tandem mass spectrometry.
Topics: 1-Deoxynojirimycin; Calibration; Child; Chromatography, Liquid; Drug Stability; Enzyme Inhibitors; Humans; Least-Squares Analysis; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2009 |
The alpha-glucosidase inhibitor miglitol suppresses postprandial hyperglycaemia and interleukin-1beta and tumour necrosis factor-alpha gene expression in rat peripheral leucocytes induced by intermittent sucrose loading.
Topics: 1-Deoxynojirimycin; Animals; Diabetes Mellitus, Experimental; Dietary Sucrose; Gene Expression; Glycoside Hydrolase Inhibitors; Hyperglycemia; Interleukin-1beta; Leukocytes, Mononuclear; Male; Models, Animal; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Sweetening Agents; Tumor Necrosis Factor-alpha | 2009 |
The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes.
Topics: 1-Deoxynojirimycin; Animals; Area Under Curve; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Dietary Sucrose; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Leukocytes; Male; Microarray Analysis; Random Allocation; Rats; Rats, Wistar; RNA, Messenger; Streptozocin; Up-Regulation | 2009 |
Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Postprandial Period | 2009 |
Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.
Topics: 1-Deoxynojirimycin; Administration, Oral; Animals; Blood Glucose; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dogs; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Hyperglycemia; Hypoglycemic Agents; Intestine, Small; Male; Random Allocation; Rats; Rats, Sprague-Dawley | 2009 |
Amplification of the inhibitory activity of miglitol by monofluorination.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Cell Line; Glycoside Hydrolase Inhibitors; Halogenation; Humans; Hypoglycemic Agents | 2009 |
The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Diabetes Mellitus; Glucose Tolerance Test; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Rats; Rats, Inbred OLETF | 2009 |
A case of insulinoma following total gastrectomy--effects of an alpha-glucosidase inhibitor on suppressing GIP and GLP-1 elevations.
Topics: 1-Deoxynojirimycin; Female; Gastrectomy; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Insulinoma; Middle Aged; Pancreatic Neoplasms; Postprandial Period | 2010 |
Changes in α-glucosidase activities along the jejunal-ileal axis of normal rats by the α-glucosidase inhibitor miglitol.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Cecum; Dietary Supplements; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Ileum; Intestinal Mucosa; Jejunum; Male; Rats; Rats, Wistar | 2010 |
Glucose supply and insulin demand dynamics of antidiabetic agents.
Topics: 1-Deoxynojirimycin; Acarbose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dietary Carbohydrates; Energy Intake; Follow-Up Studies; Gluconeogenesis; Glucose; Glycated Hemoglobin; Heart Diseases; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Intestinal Absorption; Liver; Metformin; Myocardial Infarction; Thiazolidinediones | 2010 |
The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Base Sequence; Cytokines; Diabetes Mellitus, Type 2; DNA Primers; Enzyme Inhibitors; Glucose; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Leukocytes | 2010 |
Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: effects of miglitol.
Topics: 1-Deoxynojirimycin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enzyme Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Interleukin-18; Postprandial Period | 2011 |
Amplification of the inhibitory activity and reversal of the selectivity of miglitol by C(2')-monofluorination.
Topics: 1-Deoxynojirimycin; alpha-Galactosidase; Cell Line; Enzyme Inhibitors; Halogenation; Humans; Hypoglycemic Agents; Structure-Activity Relationship | 2010 |
Targeting enteral endocrinal L-cells with dietary carbohydrates, by increasing the availability of miglitol in the intestinal lumen, leads to multi-fold enhancement of plasma glucagon-like peptide-1 levels in non-diabetic canines.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Biological Availability; Blood Glucose; Cellulose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dogs; Drug Implants; Enteroendocrine Cells; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Intestine, Small; Male; Methylcellulose; Polymers; Postprandial Period; Rats; Rats, Sprague-Dawley | 2011 |
Reduced expression of β2 integrin genes in rat peripheral leukocytes by inhibiting postprandial hyperglycemia.
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; CD18 Antigens; Disaccharidases; Enzyme Inhibitors; Gene Expression Regulation; Glycoside Hydrolase Inhibitors; Hyperglycemia; Intestine, Small; Leukocytes; Male; Microvilli; Rats; Rats, Sprague-Dawley | 2010 |
Development and validation of HPLC-UV-MS method for the control of four anti-diabetic drugs in suspected counterfeit products.
Topics: 1-Deoxynojirimycin; Acarbose; alpha-Glucosidases; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Inositol; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet | 2010 |
Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits.
Topics: 1-Deoxynojirimycin; Administration, Oral; Animals; Blood Glucose; Blood Pressure; Drug Synergism; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycogenolysis; Heart; Heart Rate; Hypoglycemic Agents; Insulin; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Peptide Fragments; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rabbits; Receptors, Glucagon | 2011 |
Ultra-performance liquid chromatography electrospray ionization-tandem mass spectrometry method for the estimation of miglitol in human plasma using metformin as the internal standard.
Topics: 1-Deoxynojirimycin; Chromatography, High Pressure Liquid; Humans; Metformin; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Statistics as Topic | 2011 |
Treatment with the α-glucosidase inhibitor miglitol from the preonset stage in Otsuka Long-Evans Tokushima Fatty rats improves glycemic control and reduces the expression of inflammatory cytokine genes in peripheral leukocytes.
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Cytokines; Drug Evaluation, Preclinical; Enzyme Inhibitors; Gene Expression; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Inflammation Mediators; Leukocytes; Male; Prediabetic State; Rats; Rats, Inbred OLETF | 2011 |
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
Topics: 1-Deoxynojirimycin; Acarbose; alpha-Glucosidases; Catalytic Domain; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Kinetics; Monosaccharides; Selenium Compounds; Starch; Sucrase-Isomaltase Complex; Sugar Alcohols; Sulfates | 2011 |
Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease.
Topics: 1-Deoxynojirimycin; Administration, Oral; Adult; Aged; Aged, 80 and over; Blood Glucose; Brachial Artery; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Endothelium, Vascular; Female; Follow-Up Studies; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Time Factors; Treatment Outcome; Ultrasonography; Vasodilation | 2012 |
Study of the inhibition of two human maltase-glucoamylases catalytic domains by different α-glucosidase inhibitors.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Catalytic Domain; Glycoside Hydrolase Inhibitors; Humans; Kinetics; Pancreatic alpha-Amylases; Pichia; Recombinant Proteins; Substrate Specificity; Teprotide | 2011 |
A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Topics: 1-Deoxynojirimycin; Aged; Biomarkers; Blood Glucose; Case-Control Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Male; Middle Aged; Monitoring, Physiologic; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Effect of the α-glucosidase inhibitor miglitol on the glucose profile in Japanese type 2 diabetic patients receiving multiple daily insulin injections.
Topics: 1-Deoxynojirimycin; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Postprandial Period; Prospective Studies; Retrospective Studies | 2012 |
Successful treatment of reactive hypoglycemia secondary to late dumping syndrome using miglitol.
Topics: 1-Deoxynojirimycin; Dose-Response Relationship, Drug; Dumping Syndrome; Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Middle Aged; Treatment Outcome | 2012 |
Intestinal alpha-glucosidase inhibitors: abdominal gas cysts.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Aged, 80 and over; alpha-Glucosidases; Enzyme Inhibitors; Female; Gases; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Intestinal Mucosa; Male; Middle Aged; Pneumatosis Cystoides Intestinalis; Predictive Value of Tests; Risk Assessment; Risk Factors | 2012 |
Miglitol, an anti-diabetic drug, inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase.
Topics: 1-Deoxynojirimycin; Adenylate Kinase; Animals; Apoptosis; Base Sequence; Cell Line; DNA Damage; DNA Primers; Endothelium, Vascular; Hydrogen Peroxide; Hypoglycemic Agents; Intercellular Adhesion Molecule-1; Mitochondria; Oxidative Stress; Phosphorylation; Reactive Oxygen Species; Vascular Cell Adhesion Molecule-1 | 2012 |
The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice.
Topics: 1-Deoxynojirimycin; Animals; Bile Acids and Salts; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Obesity; Rats; Rats, Wistar | 2013 |
Lipid lowering and antioxidant effect of miglitol in triton treated hyperlipidemic and high fat diet induced obese rats.
Topics: 1-Deoxynojirimycin; 3T3-L1 Cells; Adipogenesis; Animals; Antioxidants; Body Weight; Diet, High-Fat; Eating; Hyperlipidemias; Hypoglycemic Agents; Lipids; Liver; Male; Mice; Obesity; Polyethylene Glycols; Rats | 2013 |
Specificity of Processing α-glucosidase I is guided by the substrate conformation: crystallographic and in silico studies.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Carbohydrate Conformation; Carbohydrate Sequence; Catalytic Domain; Crystallography, X-Ray; Glucose; Glycoside Hydrolase Inhibitors; Hydrogen Bonding; Kinetics; Membrane Glycoproteins; Molecular Docking Simulation; Molecular Sequence Data; Protein Binding; Protein Structure, Secondary; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Structural Homology, Protein; Substrate Specificity; Trisaccharides | 2013 |
C-branched iminosugars: α-glucosidase inhibition by enantiomers of isoDMDP, isoDGDP, and isoDAB-L-isoDMDP compared to miglitol and miglustat.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Angiogenesis Inhibitors; Biological Products; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Imino Sugars; Molecular Conformation; Stereoisomerism; Structure-Activity Relationship | 2013 |
Miglitol prevents diet-induced obesity by stimulating brown adipose tissue and energy expenditure independent of preventing the digestion of carbohydrates.
Topics: 1-Deoxynojirimycin; Acarbose; Adipocytes, Brown; Adipose Tissue, Brown; Animals; Anti-Obesity Agents; Cell Line; Diet, High-Fat; Dietary Carbohydrates; Digestion; Eating; Energy Metabolism; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Obesity; Oxygen Consumption; Receptors, Adrenergic, beta; Signal Transduction | 2013 |
Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucose Tolerance Test; Hypoglycemic Agents; Islets of Langerhans; Male; Mice; Mice, Inbred Strains; Nitriles; Pyrrolidines; Vildagliptin | 2013 |
Inhibition of postprandial hyperglycemia by either an insulin-dependent or -independent drug reduces the expression of genes related to inflammation in peripheral leukocytes of OLETF rats.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression; Hyperglycemia; Hypoglycemic Agents; Inflammation; Insulin; Interleukin-18; Interleukin-1beta; Leukocytes, Mononuclear; Male; Pyrimidines; Rats; Rats, Inbred OLETF; Receptors, Interleukin-1; S100 Proteins; Sucrose; TNF Receptor-Associated Factor 2 | 2013 |
Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels.
Topics: 1-Deoxynojirimycin; Adamantane; Adult; Blood Glucose; Cholecystokinin; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Ghrelin; Humans; Insulin; Male; Middle Aged; Nitriles; Peptide YY; Pyrrolidines; Vildagliptin | 2014 |
A sensitive and selective method for the quantitative analysis of miglitol in rat plasma using unique solid-phase extraction coupled with liquid chromatography-tandem mass spectrometry.
Topics: 1-Deoxynojirimycin; Animals; Chromatography, Liquid; Drug Stability; Linear Models; Male; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Temperature | 2014 |
A Strategy for assessing potential drug-drug interactions of a concomitant agent against a drug absorbed via an intestinal transporter in humans.
Topics: 1-Deoxynojirimycin; Animals; Cell Line; CHO Cells; Computer Simulation; Cricetulus; Drug Interactions; Humans; Intestinal Absorption; Intestinal Mucosa; Male; Membrane Transport Proteins; Models, Biological; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 1; Sorbitol | 2014 |
Using miglitol at 30 min before meal is effective in hyperinsulinemic hypoglycemia after a total gastrectomy.
Topics: 1-Deoxynojirimycin; Blood Glucose; Drug Administration Schedule; Female; Gastrectomy; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Meals; Middle Aged; Postprandial Period | 2014 |
Distinct action of the α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion.
Topics: 1-Deoxynojirimycin; Acarbose; Animals; Enteroendocrine Cells; Glucagon-Like Peptide 1; Glucose Transporter Type 2; Glycoside Hydrolase Inhibitors; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 1; Xenopus laevis | 2015 |
Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.
Topics: 1-Deoxynojirimycin; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrimidines | 2015 |
Isolation and SAR studies of bicyclic iminosugars from Castanospermum australe as glycosidase inhibitors.
Topics: 1-Deoxynojirimycin; Alkaloids; Castanospermum; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolases; Hypoglycemic Agents; Imino Sugars; Indolizines; Piperidines; Stereoisomerism; Structure-Activity Relationship | 2015 |
Hallucinations associated with miglitol use in a patient with chronic kidney disease and hypothyroidism.
Topics: 1-Deoxynojirimycin; Aged; Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; Glycoside Hydrolase Inhibitors; Hallucinations; Humans; Hypoglycemic Agents; Hypothyroidism; Renal Insufficiency, Chronic | 2015 |
Miglitol protects against age-dependent weight gain in mice: A potential role of increased UCP1 content in brown adipose tissue.
Topics: 1-Deoxynojirimycin; Adipose Tissue, Brown; Adiposity; Aging; Animals; Diet; Energy Metabolism; Gene Expression; Hypoglycemic Agents; Ion Channels; Male; Mice; Mice, Inbred C57BL; Mitochondrial Proteins; Motor Activity; Obesity; Oxygen Consumption; Uncoupling Protein 1; Weight Gain | 2015 |
Azetidine- and N-carboxylic azetidine-iminosugars as amyloglucosidase inhibitors: synthesis, glycosidase inhibitory activity and molecular docking studies.
Topics: 1-Deoxynojirimycin; Azetidines; Chemistry Techniques, Synthetic; Enzyme Inhibitors; Glucan 1,4-alpha-Glucosidase; Glycoside Hydrolases; Imino Sugars; Inhibitory Concentration 50; Molecular Docking Simulation | 2015 |
Determination of Miglitol by Column-Switching Ion-Pair HPLC with Tris(2,2'-bipyridine)ruthenium(II)-Electrogenerated Chemiluminescence Detection.
Topics: 1-Deoxynojirimycin; 2,2'-Dipyridyl; Alkanesulfonic Acids; Chromatography, High Pressure Liquid; Coordination Complexes; Equipment Design; Humans; Hypoglycemic Agents; Limit of Detection; Luminescence; Luminescent Agents; Luminescent Measurements | 2015 |
Treatment with DPP-4I Anagliptin or α-GI Miglitol Reduces IGT Development and the Expression of CVD Risk Factors in OLETF Rats.
Topics: 1-Deoxynojirimycin; Animals; Aorta; Blood Glucose; Cardiovascular Diseases; Cell Adhesion Molecules; Cytokines; Fasting; Hyperglycemia; Hypoglycemic Agents; Interleukin-1beta; Leukocytes; Male; Postprandial Period; Pyrimidines; Rats; Rats, Inbred OLETF; Risk Factors; S100 Proteins; Tumor Necrosis Factor-alpha | 2015 |
Concurrent Therapy with a Low-carbohydrate Diet and Miglitol Remarkably Improved the Postprandial Blood Glucose and Insulin Levels in a Patient with Reactive Hypoglycemia due to Late Dumping Syndrome.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Combined Modality Therapy; Diet, Carbohydrate-Restricted; Dumping Syndrome; Glucose Tolerance Test; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Postprandial Period | 2016 |
Rapid identification of miglitol and its isomers by electrospray ionization tandem mass spectrometry.
Topics: 1-Deoxynojirimycin; Hypoglycemic Agents; Isomerism; Spectrometry, Mass, Electrospray Ionization | 2016 |
Metabolic Control of Tobacco Pollination by Sugars and Invertases.
Topics: 1-Deoxynojirimycin; beta-Fructofuranosidase; Carbohydrates; Enzyme Inhibitors; Gene Expression Regulation, Plant; Germination; Hexoses; Models, Biological; Monosaccharide Transport Proteins; Nicotiana; Plant Proteins; Pollen Tube; Pollination; Reproducibility of Results | 2017 |
Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Inositol | 2018 |
Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model.
Topics: 1-Deoxynojirimycin; Animals; Diet, High-Fat; Disease Models, Animal; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease | 2017 |
Combination of flavonoids from Oroxylum indicum seed extracts and acarbose improves the inhibition of postprandial blood glucose: In vivo and in vitro study.
Topics: 1-Deoxynojirimycin; Acarbose; alpha-Amylases; alpha-Glucosidases; Animals; Bignoniaceae; Blood Glucose; Drug Synergism; Flavanones; Flavonoids; Hypoglycemic Agents; Intestines; Male; Mice; Pancreas; Plant Extracts; Postprandial Period; Rats, Sprague-Dawley; Seeds | 2017 |
Interaction of antidiabetic α-glucosidase inhibitors and gut bacteria α-glucosidase.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Bacterial Proteins; Gastrointestinal Microbiome; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Models, Molecular; Protein Binding; Ruminococcus | 2018 |
Gut carbohydrate inhibits GIP secretion via a microbiota/SCFA/FFAR3 pathway.
Topics: 1-Deoxynojirimycin; Animals; Carbohydrate Metabolism; Fatty Acids, Volatile; Gastric Inhibitory Polypeptide; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Incretins; KATP Channels; Maltose; Mice; Receptors, G-Protein-Coupled | 2018 |
Enhanced Production of 6-(N-Hydroxyethyl)-Amino-6-Deoxy-α-L-Sorbofuranose by Immobilized Gluconobacter oxydanson Corn Stover with a pH Control Strategy in a Bubble Column Bioreactor.
Topics: 1-Deoxynojirimycin; Amino Sugars; Bioreactors; Biotechnology; Biotransformation; Cells, Immobilized; Culture Media; Gluconobacter oxydans; Hydrogen-Ion Concentration; Nitrosamines; Zea mays | 2019 |
The intestine responds to heart failure by enhanced mitochondrial fusion through glucagon-like peptide-1 signalling.
Topics: 1-Deoxynojirimycin; Animals; Cells, Cultured; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dynamins; Enteroendocrine Cells; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycoside Hydrolase Inhibitors; GTP Phosphohydrolases; Heart Failure; Ileum; Incretins; Male; Membrane Proteins; Mitochondria, Heart; Mitochondrial Dynamics; Mitochondrial Proteins; Myocytes, Cardiac; Paracrine Communication; Peptide Fragments; Rats, Inbred Dahl; Rats, Sprague-Dawley; Signal Transduction; Sodium Chloride, Dietary; Ventricular Function, Left | 2019 |
Use of a deoxynojirimycin-fluorophore conjugate as a cell-specific imaging probe targeting α-glucosidase on cell membranes.
Topics: 1-Deoxynojirimycin; Acarbose; alpha-Glucosidases; Animals; Catalytic Domain; Cell Line, Tumor; Cell Membrane; Coumarins; Dansyl Compounds; Fluorescent Dyes; Glycoside Hydrolase Inhibitors; Humans; Mice; Microscopy, Fluorescence; Molecular Docking Simulation; Protein Binding | 2019 |
Synergistic improvement of PQQ-dependent D-sorbitol dehydrogenase activity from Gluconobacter oxydans for the biosynthesis of miglitol precursor 6-(N-hydroxyethyl)-amino-6-deoxy-α-L-sorbofuranose.
Topics: 1-Deoxynojirimycin; Amino Acids; Bacterial Proteins; Bioreactors; Culture Media; Fermentation; Gene Expression; Gluconobacter oxydans; Hypoglycemic Agents; L-Iditol 2-Dehydrogenase; PQQ Cofactor; Recombinant Proteins; Sorbitol; Sorbose | 2019 |
Supramolecular azasugar clusters based on an amphiphilic fatty-acid-deoxynojirimycin derivative as multivalent glycosidase inhibitors.
Topics: 1-Deoxynojirimycin; alpha-Mannosidase; Animals; Blood Glucose; Cell Survival; Enzyme Inhibitors; Fatty Acids; Glucosamine; Glucose Tolerance Test; Hydrogen-Ion Concentration; Hypoglycemic Agents; Maltose; Mice | 2019 |
Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice.
Topics: 1-Deoxynojirimycin; Animals; Chronic Disease; Diet, High-Fat; Dietary Sucrose; Disease Models, Animal; Gastrointestinal Absorption; Gene Expression; Glucose; Insulin Resistance; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Patient Acuity; RNA, Messenger; Sodium-Glucose Transporter 1; Sorbitol | 2021 |
Resolving interactions of miglitol with normal and glycated human serum albumin by multivariate methods.
Topics: 1-Deoxynojirimycin; Binding Sites; Electrochemical Techniques; Humans; Molecular Docking Simulation; Serum Albumin, Human; Software; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet | 2021 |
N-Hydroxyethyl-1-Deoxynojirimycin (Miglitol) Restores the Counterregulatory Response to Hypoglycemia Following Antecedent Hypoglycemia.
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Epinephrine; Glucose Clamp Technique; Hypoglycemia; Hypoglycemic Agents; Insulin; Norepinephrine; Rats; Sodium | 2022 |
Flow chemistry based catalytic hydrogenation for improving the synthesis of 1-deoxynojirimycin (DNJ) from an l-sorbose derived precursor.
Topics: 1-Deoxynojirimycin; Hydrogenation; Sorbose | 2023 |